EP. 1: Shreyaskumar R. Patel, MD: Leiomyosarcoma Differing From Those Arising at Other SitesDecember 21st 2015
EP. 2: Shreyaskumar R. Patel, MD: Standard of Care for Invasive, Unresectable LeiomyosarcomaDecember 21st 2015
EP. 3: Shreyaskumar R. Patel, MD: Risk/Benefit Ratio of Using Ifosfamide in This Patient December 21st 2015
EP. 5: Shreyaskumar R. Patel, MD: Targeted Therapies Influencing Treatment Options December 21st 2015
EP. 6: Shreyaskumar R. Patel, MD: Additional Options Available for Durable Response December 21st 2015
EP. 7: Jonathan C. Trent, MD, PhD: Leiomyosarcoma Differing From Those Arising at Other SitesDecember 21st 2015
EP. 8: Jonathan C. Trent, MD, PhD: Standard of Care for Invasive, Unresectable LeiomyosarcomaDecember 21st 2015
EP. 9: Jonathan C. Trent, MD, PhD: Risk/Benefit Ratio of Using Ifosfamide in This PatientDecember 21st 2015
EP. 11: Jonathan C. Trent, MD, PhD: Targeted Therapies Influencing Treatment OptionsDecember 21st 2015
EP. 12: Jonathan C. Trent, MD, PhD: Additional Options Available for Durable ResponseDecember 21st 2015
